VOL. XCIV, NO. 247

★ WIDE MOAT STOCKS COMPARISON ★

NO ADVICE

Saturday, January 10, 2026

Stock Comparison

Mettler-Toledo International Inc. vs Vertex Pharmaceuticals Incorporated

Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.

Mettler-Toledo International Inc.

MTD · New York Stock Exchange

Market cap (USD)$30.4B
Gross margin (TTM)58.4%
Operating margin (TTM)28.6%
Net margin (TTM)21.2%
SectorHealthcare
IndustryMedical - Diagnostics & Research
CountryUS
Data as of2026-01-01
Moat score
73/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into Mettler-Toledo International Inc.'s moat claims, evidence, and risks.

View MTD analysis

Vertex Pharmaceuticals Incorporated

VRTX · NASDAQ

Market cap (USD)$119B
Gross margin (TTM)
Operating margin (TTM)
Net margin (TTM)
SectorHealthcare
IndustryBiotechnology
CountryUS
Data as of2026-01-08
Moat score
99/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into Vertex Pharmaceuticals Incorporated's moat claims, evidence, and risks.

View VRTX analysis

Comparison highlights

  • Moat score gap: Vertex Pharmaceuticals Incorporated leads (99 / 100 vs 73 / 100 for Mettler-Toledo International Inc.).
  • Segment focus: Mettler-Toledo International Inc. has 3 segments (56% in Laboratory Products and Services); Vertex Pharmaceuticals Incorporated has 3 segments (99.9% in Cystic Fibrosis CFTR Modulators).
  • Primary market structure: Oligopoly vs Quasi-Monopoly. Pricing power: Strong vs Strong.
  • Moat breadth: Mettler-Toledo International Inc. has 5 moat types across 3 domains; Vertex Pharmaceuticals Incorporated has 7 across 4.

Primary market context

Mettler-Toledo International Inc.

Laboratory Products and Services

Market

Laboratory precision weighing (balances/scales) and adjacent lab measurement & sample-prep instruments, plus related software and services

Geography

Global

Customer

Life science, chemical, academic, and testing laboratories (end-users) via direct sales and distributors

Role

Instrument OEM / software provider / service provider

Revenue share

56%

Vertex Pharmaceuticals Incorporated

Cystic Fibrosis CFTR Modulators

Market

CFTR modulator therapies for cystic fibrosis

Geography

U.S., Europe, Australia, Canada

Customer

Patients (via specialty pharmacies/payers); CF care centers

Role

Drug developer/manufacturer

Revenue share

99.9%

Side-by-side metrics

Mettler-Toledo International Inc.
Vertex Pharmaceuticals Incorporated
Ticker / Exchange
MTD - New York Stock Exchange
VRTX - NASDAQ
Market cap (USD)
$30.4B
$119B
Gross margin (TTM)
58.4%
n/a
Operating margin (TTM)
28.6%
n/a
Net margin (TTM)
21.2%
n/a
Sector
Healthcare
Healthcare
Industry
Medical - Diagnostics & Research
Biotechnology
HQ country
US
US
Primary segment
Laboratory Products and Services
Cystic Fibrosis CFTR Modulators
Market structure
Oligopoly
Quasi-Monopoly
Market share
25%-30% (estimated)
70%-78% (reported)
HHI estimate
2,440
n/a
Pricing power
Strong
Strong
Moat score
73 / 100
99 / 100
Moat domains
Demand, Supply, Legal
Legal, Demand, Financial, Supply
Last update
2026-01-01
2026-01-08

Moat coverage

Shared moat types

Service Field NetworkSwitching Costs General

Mettler-Toledo International Inc. strengths

Brand TrustData Workflow LockinCompliance Advantage

Vertex Pharmaceuticals Incorporated strengths

IP Choke PointGovernment Contracting RelationshipsBenchmark Pricing PowerRegulated Standards PipeCapacity Moat

Segment mix

Mettler-Toledo International Inc. segments

Full profile >

Laboratory Products and Services

Oligopoly

56%

Industrial Products and Services

Competitive

39%

Food Retailing Products and Services

Competitive

5%

Vertex Pharmaceuticals Incorporated segments

Full profile >

Cystic Fibrosis CFTR Modulators

Quasi-Monopoly

99.9%

Hemoglobinopathies Gene Therapy (CASGEVY)

Oligopoly

0.1%

Acute Pain (JOURNAVX)

Competitive

n/a

Want the full wide moat stocks list?

Browse the full ranking of wide moat stocks, updated with moat scores and segment context.

View the moat stocks list

Looking for expansion-stage stocks?

Proven models entering the expansion stage with unit economics that work.

View expansion-stage stocks

Curation & Accuracy

This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).

Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.